Loading
A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP is a phase 2 interventional study registered as NCT07354074 by Novartis Pharmaceuticals, with 50 participants planned, started 2026-04-28 and due to reach its primary completion in 2033-02-23. Interventions recorded: Asciminib single agent.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML), Novartis and the tag pipeline.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.